Payment overview · 2025
General Payments
$395.83
19 reported records · 11 companies
Healthcare provider profile · identity verified
William Edward Kyle, DO
Allopathic & Osteopathic Physicians|Internal Medicine · OKATIE, SC · NPI 1770758351
Verified facts
What the public records show
CMS Open Payments records show William Edward Kyle, DO received $395.83 in general payments during 2025 across 19 reported records.
Novo Nordisk Inc accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $111.62 | 28.2% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.65 | 13.8% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $34.70 | 8.8% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $33.35 | 8.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $32.68 | 8.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.89 | 7.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.44 | 6.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.87 | 5.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.20 | 5.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.23 | 4.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.20 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $395.83 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $96.25 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $81.21 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $53.95 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $34.70 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $33.35 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $32.68 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 69 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 82 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 116 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 95 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
116 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1408 | 408 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1236 | 361 |
| Amlodipine Besylate | Amlodipine Besylate | 978 | 292 |
| Levothyroxine Sodium | Levothyroxine Sodium | 731 | 198 |
| Losartan Potassium | Losartan Potassium | 724 | 214 |
| Lisinopril | Lisinopril | 590 | 177 |
| Omeprazole | Omeprazole | 498 | 167 |
| Metformin Hcl Er | Metformin Hcl | 391 | 118 |
| Metformin Hcl | Metformin Hcl | 383 | 109 |
| Metoprolol Succinate | Metoprolol Succinate | 378 | 113 |
| Simvastatin | Simvastatin | 373 | 106 |
| Hydrochlorothiazide | Hydrochlorothiazide | 353 | 103 |
| Pravastatin Sodium | Pravastatin Sodium | 325 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 286 | 96 |
| Tamsulosin Hcl | Tamsulosin Hcl | 247 | 72 |
| Sertraline Hcl | Sertraline Hcl | 198 | 57 |
| Synthroid | Levothyroxine Sodium | 194 | 51 |
| Allopurinol | Allopurinol | 188 | 49 |
| Ezetimibe | Ezetimibe | 187 | 66 |
| Glimepiride | Glimepiride | 178 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 173 | 59 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 160 | 42 |
| Gabapentin | Gabapentin | 158 | 55 |
| Atenolol | Atenolol | 152 | 46 |
| Alprazolam | Alprazolam | 150 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 143 | 65 |
| Trazodone Hcl | Trazodone Hcl | 139 | 48 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 134 | 37 |
| Carvedilol | Carvedilol | 132 | 39 |
| Alendronate Sodium | Alendronate Sodium | 122 | 38 |
| Valsartan | Valsartan | 119 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 117 | 40 |
| Eliquis | Apixaban | 116 | 33 |
| Montelukast Sodium | Montelukast Sodium | 116 | 37 |
| Mounjaro | Tirzepatide | 116 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 24 |
| Furosemide | Furosemide | 95 | 35 |
| Ozempic | Semaglutide | 95 | 23 |
| Lorazepam | Lorazepam | 92 | 27 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 89 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 35 |
| Jardiance | Empagliflozin | 82 | 23 |
| Chlorthalidone | Chlorthalidone | 79 | 25 |
| Famotidine | Famotidine | 77 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 74 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 23 |
| Finasteride | Finasteride | 71 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 21 |
| Farxiga | Dapagliflozin Propanediol | 69 | 19 |
| Spironolactone | Spironolactone | 68 | 18 |
| Irbesartan | Irbesartan | 65 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 16 |
| Meloxicam | Meloxicam | 62 | 23 |
| Lovastatin | Lovastatin | 58 | 19 |
| Bupropion Xl | Bupropion Hcl | 55 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 18 |
| Celecoxib | Celecoxib | 54 | 19 |
| Glipizide | Glipizide | 52 | 11 |
| Tramadol Hcl | Tramadol Hcl | 52 | 14 |
| Trulicity | Dulaglutide | 52 | suppressed |
| Januvia | Sitagliptin Phosphate | 50 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 13 |
| Terazosin Hcl | Terazosin Hcl | 43 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 42 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 13 |
| Ramipril | Ramipril | 40 | 11 |
| Potassium Chloride | Potassium Chloride | 39 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | 11 |
| Temazepam | Temazepam | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | 11 |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Tradjenta | Linagliptin | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 32 | suppressed |
| Prednisone | Prednisone | 31 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 12 |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 21 |
| Topiramate | Topiramate | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 13 |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 20 |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 17 |
| Diazepam | Diazepam | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Euthyrox | Levothyroxine Sodium | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 11 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $395.83 · 19 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, Cologuard Collection Kit, FARXIGA, INSPIRE, JARDIANCE, Kerendia, Korlym, Leqembi, MOUNJARO, NEXLETOL, Ozempic, PREVNAR 20, Rybelsus, The Cologuard Plus Collection Kit, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error